SAN DIEGO — Results from Cytori Therapeutics’ (NASDAQ: CYTX) preclinical fat grafting study have been published in the February issue of the Annals of Plastic Surgery. This article, entitled “Supplementation of Fat Grafts with Adipose-Derived Regenerative Cells (ADRCs) Improves Long-Term Graft Retention,” examines the science behind cell-enriched autologous fat grafting and its application to cosmetic and reconstructive surgery. The results demonstrate a doubling in graft retention in cell-enriched grafts and provide insight into the mechanisms behind this improvement. The results reinforce both commercial observations and interim data from the RESTORE 2 clinical study that was presented at the San Antonio Breast Cancer Symposium in December.
The preclinical results described in the paper support the potential clinical utility for cell-enriched fat grafts in cosmetic and reconstructive surgery. The key results include:
- Long term retention of cell-enriched autologous fat grafts was increased two-fold over controls
- Quality of the cell-enriched grafts was significantly higher than controls with an increased number of healthy fat cells and reduced formation of cysts
- Improved blood vessel density in ADRC-enriched grafts
- Demonstration of several critical growth factors expressed by ADRCs
In this study, a mouse model of autologous fat grafting was used to compare graft retention of cell-enriched fat grafts with traditional fat grafts. Retention was evaluated six and nine months after implantation. Supplemental in vitro and in vivo studies provide evidence that ADRC-enrichment improved graft retention and quality by promoting cell survival and the rapid formation of blood vessels within the graft through expression of growth factors known to promote vessel formation and prevent cell death.
The February issue of Annals of Plastic Surgery is currently available online at www.annalsplasticsurgery.com
Cytori is an emerging leader in regenerative medicine, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include our history of operating losses, the need for further financing, inherent risk and uncertainty in the protection of intellectual property rights, regulatory uncertainties regarding the collection and results of, clinical data, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori’s Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2008. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.